Competitive Technologies' Calmare(R) Medical Device Gaining Recognition


FAIRFIELD, Conn., Aug. 3, 2011 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) is pleased to note that its Calmare® Pain Therapy medical device is becoming increasingly recognized by the medical community as an effective treatment option for cancer pain. Physicians have shared with CTTC that its Calmare Scrambler Therapy™ provides significant efficacy in treating patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). CIPN is well documented in the medical journals as being refractory, or resistant, to most other treatment modalities, especially the standard multi-drug protocols for pain treatment which dramatically compromise the quality of life of many patients.

Competitive Technologies stresses the value Calmare Scrambler Therapy providers offer to patients suffering from debilitating neuropathic pain, including pain associated with cancer. A recent feature story which aired on KSL-TV (http://www.ksl.com/?nid=148&sid=16580318) and was published in the Deseret News (http://www.deseretnews.com/) highlighted the success Dr. Robert Chalmers of Utah had in treatment of a teenager who had suffered from severe pain from a nerve disorder called reflex neurovascular dystrophy, or RND, for nearly two years.  

"Calmare Scrambler Therapy is an additional treatment tool for physicians to provide to patients severely affected by cancer-related pain and chronic neuropathic pain. It is an option that is proving especially valuable for those patients who have exhausted all other pain relief treatment modalities, and especially those patients who have not found pain relief from a multi-drug treatment protocol program, including powerful opioid medications, antidepressants and anti-convulsants traditionally prescribed for such pain," said Aris Despo, CTTC's Executive Vice President. "Raising awareness of patient relief like the recent case featured in Utah helps patients and physicians find new and viable treatment options. Dr. Chalmer's successes are among the many reported to us by our growing list of Calmare Scrambler Therapy providers. We are enthused and motivated to expand our efforts to help members of the medical profession and their patients learn about our pain treatment program and how to include it in their practices."

About Competitive Technologies, Inc

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions.

CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy™" technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



            

Contact Data